Concurrent Remission of Therapy-Related Acute Myeloid Leukemia and IgG-λ MGUS During Oral Decitabine-Cedazuridine: A Case Report. [PDF]
Niscola P +4 more
europepmc +1 more source
Venetoclax plus hypomethylating agent improves response rates but not survival in <i>TP53</i>-mutated myelodysplastic syndromes. [PDF]
Canonico M +17 more
europepmc +1 more source
Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain. [PDF]
Lloret Avellá M +3 more
europepmc +1 more source
Venetoclax with azacitidine and dexamethasone: Non-cytotoxic induction therapy for T-cell leukemia and mixed-phenotype leukemia. [PDF]
Lei Y +11 more
europepmc +1 more source
Synthetic lethality in TP53-mutant acute myeloid leukemia. [PDF]
Patel SA.
europepmc +1 more source
Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma. [PDF]
Gordon MJ +11 more
europepmc +1 more source
Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study. [PDF]
Ueda T +14 more
europepmc +1 more source
Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms. [PDF]
Gangat N, Ravandi F.
europepmc +1 more source
Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine. [PDF]
Shi T +17 more
europepmc +1 more source
Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management. [PDF]
Garcia-Manero G.
europepmc +1 more source

